U.S. Archives – Page 6 of 8 – Treatment Action Group

Eight HIV/AIDS Research, Policy, and Advocacy Organizations File an Amici Curiae Brief in Staley v. Gilead – Background and Next Steps

October 30, 2019
Dorrit Walsh

On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.

TAG Comment in Response to Proposed Rulemaking: Visas: Ineligibility Based on Public Charge Grounds

October 30, 2019
Dorrit Walsh

As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).

Ensuring Community Leadership as Part of the Federal Ending the HIV Epidemic (EHE): A Plan for America

October 21, 2019
Dorrit Walsh

The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic (EHE): A Plan for America initiative.

ACT NOW: END AIDS Coalition to Offer Community Leadership Grants

October 21, 2019
Dorrit Walsh

October 21, 2019 – The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic…

Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally

October 16, 2019
Dorrit Walsh

This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…

Advocates Debrief on the Science of Daily F/TAG vs. TDF/FTC as PrEP

October 9, 2019
Dorrit Walsh

TAG, AVAC, The Well Project and the Women’s Research Initiative (WRI) co-convened this webinar on Monday, October 7. It was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as…

Following Restricted FDA Approval of Descovy As PrEP, TAG Calls on Gilead to Immediately Partner with Community for Research on Vaginal Exposure

October 8, 2019
Dorrit Walsh

TAG laments that development for the latest oral HIV pre-exposure prophylaxis (PrEP) left out cisgender women and transgender men, but welcomes the accountability provided—albeit belated—by the U.S. Food and Drug Administration (FDA) to rectify this inequity.

ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis

September 18, 2019
Dorrit Walsh

The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017

Statement on U.S. FDA Report Highlighting Gaps in Pediatric Research

August 27, 2019
Chad Cipiti

Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.

Closing the Gap in Tuberculosis Research and Development Funding Briefs

February 20, 2019
Chad Cipiti

In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.